2,2'-[(1,4-二氧代-1,4-丁烷二基)二(氧基)]二[N,N,N-三甲基-乙铵] | 306-40-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2,2'-[(1,4-二氧代-1,4-丁烷二基)二(氧基)]二[N,N,N-三甲基-乙铵]
• 中文别名: 1H-吡唑-4-甲腈,5-氨基-1-(2,3-二甲基苯基)-
• 英文名称: succinylcholine
• 英文别名: Suxamethonium；dithylin；Bernsteinsaeure-bis-(2-trimethylammonio-aethylester)；Succinylcholin；trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
• CAS: 306-40-1
• 化学式: C₁₄H₃₀N₂O₄
• 分子量: 290.403
• InChiKey: AXOIZCJOOAYSMI-UHFFFAOYSA-N

物化性质

• 沸点：
  432.48°C (rough estimate)
• 密度：
  1.0386 (rough estimate)
• 物理描述：
  Solid
• 溶解度：
  7.57e-04 g/L
• 稳定性/保质期：
  SLIGHTLY HYGROSCOPIC ... AQ SOLN UNDERGO PROGRESSIVE HYDROLYSIS WITH CORRESPONDING LOSS OF ACTIVITY & INCR IN ACIDITY. /BROMIDE/
• 分解：
  When heated to decomposition it emits toxic fumes of nitroxides.

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

代谢

丁酰胆碱在血液中被血浆胆碱酯酶迅速代谢为丁酰单胆碱，然后进一步水解（尽管更慢）为丁酸和胆碱。

Succinylcholine is rapidly metabolized by plasma cholinesterase in the bloodstream to succinylmonocholine, which is then further hydrolyzed (albeit more slowly) to succinic acid and choline.

来源:DrugBank

毒理性

• 药物性肝损伤

丁酰胆碱

Compound:succinylcholine

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

DILI 注释：无 DILI（药物性肝损伤）担忧

DILI Annotation:No-DILI-Concern

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

标签部分：无匹配

Label Section:No match

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

参考文献：M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 美国食品药品监督管理局批准的药物标签用于研究药物诱导的肝损伤，《药物发现今日》，16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank：按人类发展药物诱导肝损伤风险排名的最大参考药物清单。《药物发现今日》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：目前没有关于在母乳喂养期间使用琥珀酰胆碱的信息。由于它迅速被消除且口服吸收不良，它不太可能到达婴儿的血液或对哺乳婴儿产生任何不良反应。包括琥珀酰胆碱在内的用于剖宫产的全身麻醉方案导致了第一次哺乳时间的延迟，但琥珀酰胆碱在此结果差异中扮演的角色尚不清楚。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：一项对接受剖宫产的女性进行的随机但非盲研究比较了硬脊膜外麻醉使用布比卡因与全身麻醉使用静脉注射硫喷妥钠4 mg/kg和琥珀酰胆碱1.5 mg/kg诱导，随后使用笑气和异氟醚。与全身麻醉相比，硬脊膜外麻醉的第一次哺乳时间显著缩短（107分钟对228分钟）。这种差异可能是由于麻醉对婴儿的影响，因为全身麻醉组的婴儿的Apgar评分、神经学和适应评分显著较低。目前尚不清楚琥珀酰胆碱在此结果差异中起了多大作用。

◉ Summary of Use during Lactation:No information is available on the use of succinylcholine during breastfeeding. Because it is rapidly eliminated and poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. A general anesthetic regimen that included succinylcholine for cesarean section caused a delay in the time to the first breastfeeding, but the part that succinylcholine played in this difference in outcome in unknown. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:A randomized, but nonblinded, study in women undergoing cesarean section compared epidural anesthesia with bupivacaine to general anesthesia with intravenous thiopental 4 mg/kg and succinylcholine 1.5 mg/kg for induction followed by nitrous oxide and isoflurane. The time to the first breastfeed was significantly shorter (107 vs 228 minutes) with the epidural anesthesia than with general anesthesia. This difference was probably caused by the anesthesia's effects on the infant, because the Apgar and neurologic and adaptive scores were significantly lower in the general anesthesia group of infants. It is not known what part succinylcholine played in this difference in outcome.

来源:Drugs and Lactation Database (LactMed)

吸收、分配和排泄

• 消除途径

大约10%的给药剂量以原形在尿液中排出。

Approximately 10% of an administered dose is excreted unchanged in the urine.

来源:DrugBank

吸收、分配和排泄

• 分布容积

在14名患者中，静脉注射剂量为1毫克/千克和2毫克/千克时，平均表观分布容积分别为16.4 ± 14.7和5.6 ± 6.8毫升/千克。

At intravenous doses of 1 mg/kg and 2 mg/kg in 14 patients, the mean apparent volumes of distribution were 16.4 ± 14.7 and 5.6 ± 6.8 mL/kg, respectively.

来源:DrugBank

吸收、分配和排泄

• 清除

18名患者静脉注射1 mg/kg琥珀酰胆碱后，其平均体内血浆清除率约为4.17 ± 2.37 L/min。

The mean _in vivo_ plasma clearance of succinylcholine following an intravenous dose of 1 mg/kg in 18 patients was approximately 4.17 ± 2.37 L/min.

来源:DrugBank

吸收、分配和排泄

约10%的琥珀酰胆碱以原形排出。

... APPROX 10% OF ... /SUCCINYLCHOLINE/ IS EXCRETED UNCHANGED.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

只有极少量的琥珀酰胆碱在人类中观察到胎盘转移，且在新生儿中并未产生临床上可观察的效果。

ONLY VERY LIMITED PLACENTAL TRANSFER OF...SUCCINYLCHOLINE WAS OBSERVED IN HUMANS, & DID NOT PRODUCE CLINICALLY OBSERVABLE EFFECTS IN NEW-BORN.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2923900090

文献信息

• ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
  申请人：Meng Charles Q.

  公开号：US20140142114A1

  公开（公告）日：2014-05-22

  The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

  本发明涉及以下式（I）的新型驱虫化合物： 其中 Y和Z分别是双环碳环或双环杂环基团，或者Y或Z中的一个是双环碳环或双环杂环基团，另一个是烷基，烯基，炔基，环烷基，苯基，杂环基或杂芳基，以及变量X 1 ，X 2 ，X 3 ，X 4 ，X 5 ，X 6 ，X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物，以及它们用于治疗和预防动物寄生虫感染的用途。
• [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS<br/>[FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES
  申请人：MERIAL INC

  公开号：WO2018093920A1

  公开（公告）日：2018-05-24

  The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

  本发明提供了公式（I）的环状脱氨肽化合物，其中至少一个碳原子的立体化学构型与自然存在的环状脱氨肽PF1022A的基团Cy1、Cy2、R1、R2、R3、R4、Ra和Rb相比发生了倒置。该发明还提供了包含这些化合物的组合物，对危害动物的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体表的寄生虫。该发明还提供了一种改进的方法，用于根除、控制和预防鸟类和哺乳动物的寄生虫感染。
• DICATION COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF
  申请人：WEST CHINA HOSPITAL, SICHUAN UNIVERSITY

  公开号：US20210214304A1

  公开（公告）日：2021-07-15

  A dication compound represented by formula (I), stereoisomers having the structure of formula (I) or a mixture of the stereoisomers, a pharmaceutically acceptable salt, a solvate, or a eutectic crystal, and a composition thereof, and use of a composition, are capable of producing neuromuscular junction retardation, formed of same with a pharmaceutically acceptable carrier in the field of preparation of a medicament for muscular flaccidity.

  由式(I)表示的二聚化合物，具有式(I)结构的立体异构体或立体异构体的混合物，药学上可接受的盐，溶剂合物或共晶晶体，以及其组合物，以及组合物的使用，能够在制备用于肌肉松弛症的药物领域中与药学上可接受的载体一起形成神经肌肉接头延迟。
• MULTIFUNCTIONAL SMALL MOLECULES
  申请人：Baker, JR. James R.

  公开号：US20120259114A1

  公开（公告）日：2012-10-11

  The present invention relates to dendrimer synthesis. Specifically, the present invention relates to triazine scaffolds capable of click chemistry for one-step synthesis of functionalized dendrimers, and methods of making and using the same.

  本发明涉及树枝状大分子的合成。具体而言，本发明涉及能够进行点击化学的 三嗪支架，用于一步法合成功能化树枝状大分子，以及制造和使用该支架的方法。
• PROCESS FOR PREPARATION OF SUCCINYLCHOLINE CHLORIDE
  申请人：SEQUENT SCIENTIFIC LIMITED

  公开号：US20140100385A1

  公开（公告）日：2014-04-10

  The present invention relates to a process for the preparation of succinylcholine chloride, a pharmaceutically active compound used as skeletal muscle relaxant which comprises condensing succinic anhydride with N,N-diemthylaminoethanol using a catalyst in presence of a solvent to form bis[2-(dimethylamino)ethyl]succinate; in situ purifying the bis[2-(dimethylamino)ethyl]succinate using a base; reacting pure bis[2-(dimethylamino)ethyl]succinate with methyl chloride gas using an alcohol; and purifying the obtained crude succinylcholine chloride using water and alcohol.

  该发明涉及一种制备琥珀酰胆碱氯化物的过程，该化合物是一种用作骨骼肌松弛剂的药用活性化合物，包括在溶剂存在的条件下，利用催化剂将琥珀酸酐与N,N-二甲基氨基乙醇缩合，形成双[2-(二甲基氨基)乙基]琥珀酸酯；原位利用碱净化双[2-(二甲基氨基)乙基]琥珀酸酯；用醇反应纯净的双[2-(二甲基氨基)乙基]琥珀酸酯与氯甲烷气体；并利用水和醇净化所得的粗琥珀酰胆碱氯化物。

表征谱图